rst-line therapy for Helicobacter pylori eradication

Materials and methods: Th is is a prospective, open-label, single-centre study. Th e study involved 86 consecutive patients with nonulcer dyspepsia. All patients were randomly assigned into 2 study groups at a 2:1 ratio using random sampling numbers. Th e fi rst group of patients were administered a sequential treatment: pantoprazole 2 × 40 mg and amoxicillin 2 × 1000 mg for the fi rst 7 days and pantoprazole 2 × 40 mg, metronidazole 2 × 500 mg, and tetracycline 4 × 500 mg for the remaining 7 days. Th e second group of patients were administered pantoprazole 2 × 40 mg, amoxicillin 2 × 1000 mg, and clarithromycin 2 × 500 mg (PAC) for 14 days. Eradication was defi ned as the absence HP as assessed with the (14-C) urea breath test 4 weeks aft er the end of the antimicrobial therapy.